Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | BPTF | Q12830 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | AHR | P35869 | 3/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | F7 | P08709 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | F3 | P13726 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7091839 | 0.86 | CA12 (0.71) | CA12CA1CA2CA9PTGS1 | |
| SCHEMBL1144770 | 0.85 | ESR1 (0.53) | CA12CA1CA2CA9CYP2A6 | |
| SCHEMBL30260844 | 0.85 | ESR1 (0.53) | CA12CA1CA2CA9CYP2A6 | |
| Ethoxycarbonyl Group SCHEMBL27521817 | 0.84 | CA12 (0.43) | CA12CA1CA2CA9PTGS1 | |
| SCHEMBL8533738 | 0.81 | CA12 (0.53) | CA12CA1CA2CA9CYP2A6 | |
| SCHEMBL1035515 | 0.81 | CA12 (0.56) | CA12CA1CA2CA9CYP2A6 | |
| SCHEMBL29736936 | 0.81 | CA12 (0.56) | CA12CA1CA2CA9CYP2A6 | |
| SCHEMBL516725 | 0.81 | CA1 (0.75) | CA12CA1CA2CA9CYP2A6 | |
| SCHEMBL3793779 | 0.81 | CA12 (0.56) | CA12CA1CA2CA9CYP2A6 | |
| SCHEMBL5254762 | 0.80 | L3MBTL1 (0.54) | CA12CA1CA2CA9BPTF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197376-A1 | PYRAZINE AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2025-06-19 | — | — | US | disclosed |
| WO-2025099444-A1 | N-Acetylserotonin (NAS) Analogues | Beckley Psytech Limited (GB) | 2025-05-15 | — | — | WO | disclosed |
| EP-4499631-A1 | PYRAZINE AMIDE DERIVATIVES | Novartis AG (CH) | 2025-02-05 | — | — | EP | disclosed |
| EP-4247790-B1 | STING ANTAGONISTS AND USES THEREOF | REGOR PHARMACEUTICALS INC (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118591538-A | Pyrazinamide derivatives | 诺华股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-12012411-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-18 | — | — | US | disclosed |
| US-20240002368-A1 | STING ANTAGONISTS AND USES THEREOF | REGOR PHARMACEUTICALS, INC. | 2024-01-04 | — | — | US | disclosed |
| CN-116867768-A | STING antagonists and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2023-10-10 | — | — | CN | disclosed |
| WO-2023180964-A1 | PYRAZINE AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2023-09-28 | — | — | WO | disclosed |
| EP-4247790-A1 | STING ANTAGONISTS AND USES THEREOF | Qilu Regor Therapeutics Inc. (CN) | 2023-09-27 | — | — | EP | disclosed |
| EP-2565192-A1 | ANTICANCER AGENT | The University of Tokyo (JP) | 2013-03-06 | — | — | EP | disclosed |
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | disclosed |
| EP-2532656-A1 | GPR119 AGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-20120245344-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | disclosed |
| EP-2474540-A1 | GPR119 AGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| WO-2012069917-A1 | BICYCLIC GPR119 MODULATORS | LUPIN LIMITED (IN) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012069917-A1 | BICYCLIC GPR119 MODULATORS | LUPIN LIMITED (IN) | 2012-05-31 | — | — | WO | disclosed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | disclosed |
| CN-101646656-A | Pyrimidine hydrazide compounds as the PGDS inhibitor | SANOFI AVENTIS FR | 2010-02-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002368-A1 | STING ANTAGONISTS AND USES THEREOF | STING1, TBK1, CGAS | CA12 4383/4885CA1 4641/4885CA2 2460/4885 |
| US-20250197376-A1 | PYRAZINE AMIDE DERIVATIVES | SIRT5, GLS2, ARG2 | CA12 4034/4885CA1 4496/4885CA2 3238/4885 |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, HRH4 | CA12 4294/4885CA1 3848/4885CA2 2182/4885 |
| US-20120245344-A1 | GPR119 AGONIST | GPR119, GPR4, GPR55 | CA12 3630/4885CA1 4098/4885CA2 1725/4885 |
| US-12012411-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | CA12 4806/4885CA1 4869/4885CA2 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.